Anticoagulation and Antiplatelet Therapy After Aortic Stenting
After aortic stent placement, dual antiplatelet therapy (DAPT) with aspirin 75-100 mg plus clopidogrel 75 mg daily for up to 6 months is the recommended default strategy, based on the most recent high-quality evidence from complex aortic interventions.
Evidence-Based Recommendations
For Aortic Stenting (Endovascular Aortic Repair)
The most relevant and recent evidence comes from the 2024 US Aortic Research Consortium analysis of 1,525 patients undergoing fenestrated/branched endovascular aortic repair (F/BEVAR) 1. This study demonstrated that DAPT (aspirin + clopidogrel) provided superior target artery patency compared to single antiplatelet therapy (SAPT), with a hazard ratio of 0.48 (95% CI 0.27-0.84, p=0.01), without increasing bleeding complications, mortality, or reintervention rates.
Specific Regimen
Start at discharge:
- Aspirin 75-100 mg daily PLUS
- Clopidogrel 75 mg daily (after appropriate loading dose of 600 mg or >5 days maintenance therapy)
- Duration: Up to 6 months as default
This aligns with the 2024 ESC Guidelines for chronic coronary syndromes, which recommend DAPT consisting of aspirin 75-100 mg and clopidogrel 75 mg daily for up to 6 months as the default antithrombotic strategy after stenting 2.
Duration Considerations
The 2024 US-ARC data showed that duration of DAPT (1 month vs 6 months vs 1 year) did not significantly affect target artery patency 1. However, given the superior patency outcomes with DAPT and absence of increased bleeding risk, 6 months represents a reasonable balance.
Shortened Duration (1-3 months)
Consider shortening DAPT to 1-3 months if:
- Very high risk of life-threatening bleeding exists 2
- Patient is not at high bleeding risk nor high ischemic risk 2
The 2024 ESC guidelines support stopping DAPT after 1-3 months in carefully selected patients 2.
Special Populations
Patients Requiring Oral Anticoagulation (e.g., Atrial Fibrillation)
If the patient has an indication for anticoagulation (CHA₂DS₂-VASc ≥2 in males, ≥3 in females):
- Initial period (≤1 week post-stent): Triple therapy (OAC + aspirin + clopidogrel)
- After 1 week: Stop aspirin, continue dual therapy with OAC + clopidogrel for up to 6 months 2
- After 6 months: OAC monotherapy lifelong
Prefer NOACs over warfarin when combining with antiplatelet therapy, as they reduce bleeding risk 2, 3, 2.
The evidence strongly supports this approach: A 2021 meta-analysis showed that OAC with antiplatelet therapy increased bleeding risk (HR 0.54 for OAC alone vs OAC+APT) without reducing stroke risk 4. Multiple guidelines now recommend early aspirin cessation (≤1 week) after uncomplicated stenting in anticoagulated patients 2, 3, 2.
Patients with Aspirin Intolerance
Clopidogrel 75 mg daily is recommended as a safe and effective alternative to aspirin monotherapy 2, 5, 2. This applies both during DAPT (if aspirin cannot be used) and for long-term monotherapy.
Long-Term Therapy (After Initial DAPT Period)
After completing 6 months of DAPT, transition to:
- Aspirin 75-100 mg daily lifelong (preferred) 2, 5, 2
- OR Clopidogrel 75 mg daily if aspirin intolerant 2, 5, 2
This recommendation is Class I, Level A evidence for patients with prior stenting 2.
Critical Pitfalls to Avoid
Do not use anticoagulation alone to reduce cardiovascular ischemic events in peripheral arterial/aortic disease without a specific indication (e.g., atrial fibrillation) 5, 6, 7
Do not continue triple therapy long-term in anticoagulated patients—the bleeding risk outweighs benefits. Early aspirin cessation is key 2, 3, 2
Do not use DAPT or anticoagulation for aortic atheromatous plaques without stenting—they provide no benefit and increase bleeding 6
Avoid premature discontinuation of antiplatelet therapy, as this increases thrombotic risk, particularly in the first 6 months 8
Practice Pattern Reality
The 2024 US-ARC data revealed significant practice variation: 49.6% used DAPT, 28.8% SAPT, 13.6% SAPT+anticoagulant, and smaller percentages used other regimens 1. Despite this variation, DAPT demonstrated the clearest benefit for branch vessel patency without safety penalties, supporting its use as the default strategy.